TLS和PD-1/PD-L1信号通路在肝细胞癌免疫治疗方面的研究进展  

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma

作　　者：乔浩东 刘一璠 梁泽 郭怀斌[1] Hao-Dong QIAO;Yi-Fan LIU;Ze LIANG;Huai-Bin GUO(Department of Hepatobiliary Surgery,Hebei General Hospital,Shijiazhuang 050051,China)

机构地区：[1]河北省人民医院肝胆外科,石家庄050051

出　　处：《医学新知》2023年第5期373-380,共8页New Medicine

基　　金：河北省医学适用技术跟踪项目(GZ2021033)。

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)是全球最常见的恶性肿瘤之一。近年来发现程序性死亡因子1及其受体(programmed cell death-1 and its ligand,PD-1/PD-L1)与HCC的产生和发展密切相关,为免疫治疗提供了一个新方向。然而,抗PD-1/PD-L1免疫治疗缺乏有效的生物标志物。最新研究发现,三级淋巴结构(tertiary lymphoid structures,TLS)对HCC的抗PD-1/PD-L1免疫治疗效果有一定的预测价值。本文对TLS和PD-1/PD-L1信号通路的发生过程,以及二者在肝细胞癌中的表达和临床中的具体研究进展作一综述,以期为TLS和PD-1/PD-L1信号通路在肝细胞癌中的应用前景提供新的参考。In the entire world,hepatocellular carcinoma(HCC)is one of the most prevalent cancers.The discovery that HCC is intimately linked to programmed cell death-1 and its ligand(PD-1/PD-L1)in recent years has opened up new possibilities for immunotherapy.However,there are no reliable biomarkers for anti-PD-1/PD-L1 immunotherapy.The latest research has found that tertiary lymphoid structures(TLS)have certain predictive value for the anti PD-1/PD-L1 immunotherapy effect of HCC.This paper analyzes the potential of TLS and PD-1/PD-L1 signaling pathway in hepatocellular carcinoma and covers the mechanism of TLS and PD-1/PD-L1 signaling route,their expression in hepatocellular carcinoma,and particular research developments in the clinic.

关 键 词：肝细胞癌 免疫治疗 PD-1/PD-L1信号通路 三级淋巴结构 

分 类 号：R735.7[医药卫生—肿瘤]